Form 4: Enliven Therapeutics Director Rahul D. Ballal Acquires Stock Options

Director Rahul D. Ballal of Enliven Therapeutics acquired stock options exercisable for 20,491 shares of common stock on February 6, 2025.

Summary

• On February 6, 2025, Rahul D. Ballal, a director of Enliven Therapeutics, Inc. (ELVN), acquired stock options representing the right to buy 20,491 shares of common stock.
• The exercise price of these options is $22.47 per share.
• The options vest on the earlier of the first anniversary of the 2025 annual meeting or the date of the 2026 annual meeting, contingent upon Ballal's continued service as a non-employee director.
• The options expire on February 6, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of the options is contingent upon the director's continued service, aligning his interests with the company's long-term success.

Industry Context

Form 4 filings are routine disclosures of insider transactions, providing transparency to the market regarding the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates

Keywords

Enliven Therapeutics, ELVN, stock options, director, Rahul D. Ballal, Form 4, beneficial ownership, securities